CMS (Centers for Medicare and Medicaid Services): no to brain cancer MRS (magnetic resonance spectroscopy)
This article was originally published in Clinica
Executive Summary
The Centers for Medicare & Medicaid Services has decided not to cover magnetic resonance spectroscopy as a tool for diagnosing brain cancer after concluding that the evidence is currently not adequate to justify coverage. The 11 clinical trials currently available are generally lacking because they are too small and look at varying outcomes criteria, the agency said.